Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents

JACC: Cardiovascular Interventions

Volumn 6, Issue 3, 2013, Pages 274-281

  Zeller, Thomas ^a   Dake, Michael D ^b   Tepe, Gunnar ^c   Brechtel, Klaus ^c   Noory, Elias ^a   Beschorner, Ulrich ^a   Kultgen, Patricia L ^d   Rastan, Aljoscha ^a  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Klinikum Rosenheim   (Germany)

^d Med Institute Inc Lafayette   (United States)

Author keywords

Drug eluting stent(s); Femoral artery; In stent restenosis; Paclitaxel; Peripheral occlusive artery disease; Revascularization

Indexed keywords

PACLITAXEL; ALLOY; CARDIOVASCULAR AGENT; NITINOL;

ADULT; AGED; ANGIOGRAPHY; ANKLE BRACHIAL INDEX; ARTICLE; BODY MASS; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG ELUTING STENT; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IN-STENT RESTENOSIS; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NITINOL STENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; REVASCULARIZATION; SMOKING; VASCULAR PATENCY; WALKING; WALKING SPEED; CANADA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; EQUIPMENT; EUROPE; EXERCISE TEST; FEMORAL ARTERY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; PROSPECTIVE STUDY; PROSTHESIS; PROSTHESIS FAILURE; RECURRENT DISEASE; REGISTER; RISK FACTOR; SOUTH KOREA; STENOSIS, OCCLUSION AND OBSTRUCTION; TIME; TREATMENT OUTCOME;

AGED; ALLOYS; ANGIOPLASTY, BALLOON; ANKLE BRACHIAL INDEX; CANADA; CARDIOVASCULAR AGENTS; CONSTRICTION, PATHOLOGIC; DISEASE-FREE SURVIVAL; DRUG-ELUTING STENTS; EUROPE; EXERCISE TEST; FEMALE; FEMORAL ARTERY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; PROSTHESIS FAILURE; QUESTIONNAIRES; RECURRENCE; REGISTRIES; REPUBLIC OF KOREA; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 84882247516     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2012.12.118     Document Type: Article

References (34)

1. Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation 2007;115:2745-9.
2. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006;354:1879-88.
3. Laird JR, Katzen BT, Scheinert D, et al., for the RESILIENT Investigators. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv 2010;3:267-76.
4. Dick P, Wallner H, Sabeti S, et al. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv 2009;74:1090-5.
5. Dake MD, Ansel GM, Jaff MR, et al., for the ZILVER-PTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelvemonth ZILVER-PTX randomized study results. Circ Cardiovasc Interv 2011;4:495-504.
6. Norgren L, Hiatt WR, Dormandy JA, et al., for the TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007;45:Suppl S:S5-67.
7. Bosiers M, Torsello G, Gissler HM, et al. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther 2009;16:261-9.
8. Krankenberg H, Schlüter M, Steinkamp HJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the Femoral Artery Stenting Trial (FAST). Circulation 2007;116:285-92.
9. Bosiers M, Deloose K, Callaert J, et al. Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg 2011;54:1042-50.
10. Iida O, Soga Y, Hirano K, et al. Long-term outcomes and risk stratification of patency following nitinol stenting in the femoropopliteal segment: retrospective multicenter analysis. J Endovasc Ther 2011;18:753-61.
11. Soga Y, Iida O, Hirano K, et al. Utility of new classification based on clinical and lesional factors after self-expandable nitinol stenting in the superficial femoral artery. J Vasc Surg 2011;54:1058-66.
12. Gur I, Lee W, Akopian G, Rowe VL, Weaver FA, Katz SG. Clinical outcomes and implications of failed infrainguinal endovascular stents. J Vasc Surg 2011;53:658-66, discussion 667.
13. Dick P, Sabeti S, Mlekusch W, et al. Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis: initial experience. Radiology 2008;248:297-302.
14. Tosaka A, Soga Y, Iida O, et al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol 2012;59: 16-23.
15. Kastrati A, Mehilli J, von Beckerath N, et al., for the ISAR-DESIRE Study Investigators. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005;293:165-71.
16. Kolh P, Wijns W, Danchin N, et al., for the Task Force on Myocardial Revascularization of the ESC and the EACTS, EAPCI. Guidelines on myocardial revascularization. Eur J Cardiothorac Surg 2010;38;Suppl: S1-52.
17. King SB 3rd, Smith SC, Jr., Hirshfeld JW, Jr., et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008;51:172-209.
18. Dake MD, Scheinert D, Tepe G, et al. Nitinol stents with polymerfree paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the ZILVER-PTX single-arm clinical study. J Endovasc Ther 2011;18:613-23.
19. Zeller T, Macharzina R, Tepe G. The potential role of DES in peripheral in-stent restenosis. J Cardiovasc Surg (Torino) 2010;51: 561-5.
20. Dake MD, Van Alstine WG, Zhou Q, Ragheb AO. Polymer-free paclitaxel-coated Zilver PTX stents - evaluation of pharmacokinetics and comparative safety in porcine arteries. J Vasc Interv Radiol 2011;22:603-10.
21. Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP. Clinical trials for claudication: assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists. Circulation 1995;92: 614-21.
22. Laird JR, Jr., Yeo KK, Rocha-Singh K, et al. Excimer laser with adjunctive balloon angioplasty and heparin-coated self-expanding stent grafts for the treatment of femoropopliteal artery in-stent restenosis: twelve-month results from the SALVAGE study. Catheter Cardiovasc Interv 2012;80:852-9.
23. Silingardi R, Cataldi V, Moratto R, Azzoni I, Veronesi J, Coppi G. Mechanical thrombectomy in in-stent restenosis: preliminary experience at the iliac and femoropopliteal arteries with the Rotarex system. J Cardiovasc Surg (Torino) 2010;51:543-50.
24. Trentmann J, Charalambous N, Djawanscher M, Schäfer JP, Jahnke T. Safety and efficacy of directional atherectomy for the treatment of in-stent restenosis of the femoropopliteal artery. J Cardiovasc Surg (Torino) 2010;51:551-60.
25. Yeo KK, Malik U, Laird Jr. Outcomes following treatment of femoropopliteal in-stent restenosis: a single center experience. Catheter Cardiovasc Interv 2011;78:604-8.
26. Zeller T, Rastan A, Sixt S, et al. Long-term results after directional atherectomy of femoro-popliteal lesions. J Am Coll Cardiol 2006;48: 1573-8.
27. Zeller T, Frank U, Bürgelin K, et al. [Long-term results after recanalization of acute and subacute thrombotic occlusions of the infra-aortic arteries and bypass-grafts using a rotational thrombectomy device]. Rofo 2002;174:1559-65.
28. Axel DI, Kunert W, Göggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-45.
29. Scheller B, Speck U, Romeike B, et al. Contrast media as carriers for local drug delivery: successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J 2003;24:1462-7.
30. Shammas NW, Shammas GA, Helou TJ, Voelliger CM, Mrad L, Jerin M. Safety and 1-year revascularization outcome of SilverHawk atherectomy in treating in-stent restenosis of femoropopliteal arteries: a retrospective review from a single center. Cardiovasc Revasc Med 2012;13:224-7.
31. Shammas NW, Shammas GA, Hafez A, Kelly R, Reynolds E, Shammas AN. Safety and one-year revascularization outcome of excimer laser ablation therapy in treating in-stent restenosis of femoropopliteal arteries: a retrospective review from a single center. Cardiovasc Revasc Med 2012;13:341-4.
32. Werner M, Scheinert D, Henn M, et al. Endovascular brachytherapy using liquid beta-emitting rhenium-188 for the treatment of longsegment femoropopliteal in-stent stenosis. J Endovasc Ther 2012;19: 467-75.
33. Stabile E, Virga V, Salemme L, et al. Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis. J Am Coll Cardiol 2012;60:1739-42.
34. Robinson WP 3rd, Nguyen LL, Bafford R, Belkin M. Results of second-time angioplasty and stenting for femoropopliteal occlusive disease and factors affecting outcomes. J Vasc Surg 2011;53:651-7.